Evolution Biotechnologies founder Dr. David Harper interviewed for the financial website SeekingAlpha
Dr. David Harper, the founder of Evolution Biotechnologies(www.evolutionbiotech.com), has been interviewed for the US financial website SeekingAlpha (seekingalpha.com). The interview covered both Dr. Harper’s previous work on bacteriophage therapy and the new technologies being developed by Evolution Biotechnologies.
The SeekingAlpha website states: “Today I had the privilege of interviewing Dr. David Harper, who just recently departed as Chief Science Officer of AmpliPhi Biosciences (OTCQB:APHB). Founder of the infectious disease pioneer Biocontrol, which conducted the first human clinical trial of a bacteriophage, Dr. Harper is a member of the Alternatives to Antibiotics panel, a collaboration between the Wellcome Trust and the UK Department of Health. We discuss the growing threat to our healthcare system posed by drug-resistant bacteria, some of the alternatives to conventional antibiotics the panel is looking at, and some of the companies in the space he believes investors should keep their eyes on. In the interview he provides an insider’s view on the work that has been done to date with bacteriophages, discusses their potential use as a biological control, and gives us the lowdown on his new venture, Evolution Biotechnologies.“
The thirty minute interview is available fromhttp://seekingalpha.com/article/3438366-candid-one-on-one-interview-with-infectious-disease-expert-dr-david-harper-recently-departed-cso-of-ampliphi-biosciences?auth_param=179i73:1asq21l:71ff7f46d692bc8cbeec60d24a77e500&uprof=75&dr=1
About Evolution Biotechnologies
Evolution Biotechnologies (UK company 09473027) has been established to extend the application of biological control from its agricultural roots into areas of biomedical importance. The company’s initial targets have both significant unmet need and high market potential. The first stage of Evolution’s work will be based on the outcomes of a successful feasibility study on biological control of the house dust mite. The potential for developing a biological control for the bed bug will also be evaluated, along with the potential for additional targets.
About biological control
Biological control is highly specific in nature, and is perceived as environmentally friendly. The US Environmental Protection Agency (EPA) has stated that “Since biopesticides tend to pose fewer risks than conventional pesticides, EPA generally requires much less data to register a biopesticide”.Biological control methodologies have been extensively used in the agricultural sector and provide a “green” alternative to existing chemical approaches, especially where there are concerns over toxicity or resistance. Despite the validated route through the regulatory process and onto the market, application in the domestic and medical settings has received only limited attention to date.
This document contains certain forward-looking statements – i.e., statements that are not historical facts, including statements about our beliefs and expectations. These statements are based on plans, estimates and projections at the time we make the statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement.